principl
advanc
immunoglobulin
replac
therapi
primari
immunodefici
melvin
today
seem
quit
straightforward
give
igg
patient
immun
defici
involv
decreas
antibodi
product
interest
reflect
although
serum
therapi
use
earli
treatment
gener
involv
use
serum
convalesc
patient
hors
immun
specif
bacteria
toxin
primari
immun
defici
pid
yet
recogn
penicillin
yet
discov
hightit
serum
specif
therapi
common
infect
pneumococc
pneumonia
world
war
ii
concentr
human
immun
globulin
becam
avail
widespread
use
bruton
publish
first
report
use
immun
serum
globulin
isg
treat
patient
pid
studi
work
group
hypogammaglobulinemia
unit
kingdom
firmli
establish
benefit
regular
isg
inject
treatment
famili
ill
set
dosag
mgkgweek
earli
prepar
igg
could
safe
given
intraven
licens
unit
state
sinc
time
purifi
bettertoler
igg
prepar
becom
avail
widespread
interest
subcutan
rather
intraven
administr
dose
igg
use
patient
pid
escal
steadili
increasingli
ambiti
goal
prevent
infect
endorgan
damag
unfortun
also
number
remind
treatment
blood
product
carri
real
potenti
risk
includ
transmiss
bloodborn
infect
recent
use
highdos
intraven
immunoglobulin
igiv
antiinflammatori
effect
diseas
kawasaki
syndrom
immunomodulatori
effect
autoimmun
diseas
increas
demand
preciou
commod
simplifi
discuss
product
usual
denot
rout
administr
ie
intraven
igiv
subcutan
igsc
intramuscular
igim
articl
use
inclus
abbrevi
isg
refer
polyclon
human
immun
globulin
prepar
immun
serum
globulin
stringent
safeti
standard
desir
provid
antibodi
wide
rang
pathogen
need
produc
product
consist
toler
efficaci
led
largescal
industri
product
igg
concentr
may
contain
antibodi
unit
plasma
per
batch
goal
may
seem
odd
desir
assur
safeti
use
limit
number
wellcharacter
usual
relat
plasma
donor
individu
patient
decad
sinc
igiv
introduc
wit
recognit
hiv
bloodborn
viru
outbreak
hepat
c
transmiss
igiv
blood
product
earli
increas
concern
transmiss
prion
caus
spongiform
encephalopathi
therefor
reduc
risk
transmiss
known
well
possibl
emerg
bloodborn
diseas
becom
one
import
consider
govern
regul
food
drug
administr
fda
unit
state
plasma
fraction
protein
therapeut
industri
multipl
safeti
step
use
purif
therapeut
igg
concentr
blood
step
summar
fall
four
major
categori
summar
box
plasma
use
product
therapeut
protein
isg
obtain
specif
purpos
plasmapheresi
term
sourc
plasma
although
plasma
donat
whole
blood
recov
plasma
still
use
well
product
market
unit
state
must
made
plasma
obtain
unit
state
fda
regul
govern
donor
select
plasma
collect
avail
internet
donor
must
complet
questionnair
undergo
physic
examin
normal
blood
count
liver
function
test
use
plasma
consid
unit
plasma
test
serolog
marker
known
bloodborn
diseas
discard
found
posit
plasma
servic
use
quarantin
inventori
hold
procedur
individu
unit
even
test
neg
know
pathogen
store
separ
donor
return
provid
anoth
unit
plasma
second
subsequ
donat
also
test
neg
previous
obtain
unit
use
computer
databas
enabl
track
product
deriv
even
part
given
plasma
donat
patient
receiv
bloodderiv
protein
encourag
keep
care
record
lot
number
name
product
receiv
donor
ever
determin
incub
undetect
potenti
bloodborn
diseas
eg
slowviru
encephalopathi
emerg
virus
hepat
c
earli
west
nile
viru
recent
lookback
program
activ
patient
receiv
product
contain
plasma
donor
identifi
examin
test
treat
necessari
manufactur
process
isg
product
current
market
unit
state
includ
least
one
step
coldalcohol
fraction
process
develop
cohn
colleagu
earli
day
world
war
ii
differ
manufactur
use
differ
purif
step
includ
differ
column
chromatographi
protocol
produc
final
product
highli
enrich
igg
product
essenti
free
igm
contain
least
small
amount
iga
properti
isg
product
current
market
unit
state
summar
tabl
product
current
avail
unit
state
contain
igg
contain
subclass
igg
approxim
ratio
concentr
normal
plasma
test
spectrum
titer
multipl
differ
specif
antibodi
given
lot
product
requir
feder
standard
mandat
minim
titer
antibodi
measl
viru
present
current
fda
guidelin
licens
igiv
prepar
avail
internet
similar
standard
appli
licensur
isg
intend
administr
intramuscular
subcutan
rout
product
current
market
unit
state
licens
guidelin
effect
igg
molecul
concentr
solut
tend
aggreg
bring
crystalliz
fragment
fc
close
proxim
fc
portion
activ
complement
crosslink
fcgreceptor
lead
product
mediat
caus
advers
reaction
igg
infus
current
avail
isg
product
contain
excipi
amino
acid
sugar
includ
minim
format
aggreg
preserv
igg
monomer
state
excipi
differ
differ
product
list
tabl
use
product
certain
excipi
may
inadvis
specif
patient
eg
sucros
patient
risk
renal
damag
product
contain
prolin
patient
disord
metabol
amino
acid
product
contain
maltos
diabet
patient
whose
glucos
monitor
might
give
fals
read
sugar
mani
product
treat
low
ph
bottl
low
ph
well
buffer
capac
lowph
solut
limit
howev
low
ph
problemat
none
product
current
market
unit
state
even
intend
intramuscular
subcutan
use
contain
thimeros
preserv
product
requir
refriger
storag
other
shown
satisfactori
stabil
room
temperatur
brought
room
temperatur
administr
content
salt
concentr
igg
vari
well
product
licens
administr
rout
thu
select
appropri
product
must
individu
patient
despit
use
larg
donor
pool
spectrum
antibodi
concentr
certain
specif
antibodi
presenc
trace
amount
plasma
protein
differ
prepar
also
differ
differ
may
lead
unpredict
idiosyncrat
differ
toler
differ
product
individu
patient
therefor
igg
product
consid
interchang
gener
physician
notifi
may
want
slow
rate
infus
administ
premed
andor
give
igg
close
observ
patient
must
given
product
receiv
previous
dilemma
aris
assur
absenc
bloodborn
pathogen
igg
prepar
igg
may
complex
impair
detect
virus
pathogen
without
actual
inactiv
complex
viru
particl
bound
igg
usual
chemic
properti
differ
virus
thu
presenc
antibodi
viru
may
caus
partit
virusantibodi
complex
away
product
purif
step
would
remov
uncomplex
viru
phenomenon
probabl
contribut
transmiss
hepat
c
plasma
contain
antibodi
viru
exclud
pool
use
manufactur
isg
time
sensit
test
viru
avail
avoid
problem
anim
virus
prion
properti
similar
import
human
pathogen
human
like
antibodi
spike
unit
donor
plasma
run
scaleddown
product
step
assess
abil
step
remov
andor
inactiv
viru
virus
list
tabl
togeth
human
virus
intend
simul
note
signific
remov
mani
intact
virus
accomplish
cohn
coldalcohol
precipit
step
use
initi
purif
iggcontain
fraction
plasma
two
major
target
viral
inactiv
protein
coat
nonenvelop
virus
lipid
envelop
envelop
virus
gener
surfac
protein
nonenvelop
virus
sensit
inactiv
low
ph
proteolyt
enzym
heat
pasteur
lipid
protein
structur
envelop
virus
inactiv
envelop
virus
gener
requir
dissolut
lipid
envelop
accomplish
product
treatment
fatti
acid
fatti
alcohol
solventdeterg
combin
tri
nbutyl
phosphatetriton
mani
product
also
process
passag
filter
nanomet
pore
size
remov
mani
viru
particl
size
regardless
chemic
characterist
assess
need
igg
replac
augment
given
patient
usual
requir
indepth
understand
patient
condit
underli
diagnosi
patient
confirm
diagnos
known
result
sever
antibodi
defici
sever
combin
immunodefici
xlink
agammaglobulinemia
wiskottaldrich
syndrom
hyperigm
syndrom
diagnosi
alon
may
provid
suffici
ground
initi
igg
replac
therapi
soon
establish
pattern
infect
famili
histori
physic
examin
flow
cytometri
usual
lead
readili
diagnosi
confirm
molecular
analysi
patient
mutat
patient
present
recurr
infect
symptom
complex
may
may
caus
infect
decis
start
igg
therapi
base
laboratori
data
demonstr
antibodi
defici
defici
respons
appropri
vaccin
well
evid
increas
morbid
caus
infect
use
measur
specif
antibodi
titer
vaccin
respons
help
determin
whether
igg
supplement
may
indic
given
patient
discuss
extens
elsewher
beyond
scope
articl
guidelin
diagnosi
manag
pid
use
igg
replac
antibodydefici
diseas
promulg
immun
defici
foundat
joint
council
allergi
asthma
allergi
unit
state
jcaai
present
meet
european
societi
immun
defici
help
scheme
abbrevi
latter
reproduc
box
mani
patient
antibodi
defici
may
transient
patient
includ
low
birth
weight
babi
infant
delay
develop
full
spectrum
necessari
humor
respons
older
children
adult
given
cytotox
chemotherapi
cancer
patient
given
cytotox
immunosuppress
therapi
autoimmun
diseas
andor
prevent
transplant
reject
nearli
patient
receiv
hematopoiet
stem
cell
transplant
sever
combin
reevalu
period
determin
igg
replacementaugment
still
necessari
reevalu
typic
perform
patient
igg
therapi
least
sever
month
usual
involv
measur
specif
antibodi
respons
administr
protein
polysaccharid
vaccin
commerci
avail
prepar
enrich
iga
igm
patient
isol
iga
defici
gener
consid
candid
igg
supplement
patient
signific
morbid
associ
low
absent
iga
level
check
specif
igg
antibodi
vaccin
respons
howev
condit
may
coexist
part
broader
immun
defici
laboratori
use
broad
rang
normal
igg
level
patient
meet
rigor
criteria
common
variabl
hypogammaglobulinemia
also
term
common
variabl
immun
defici
still
may
benefit
igg
supplement
convers
patient
igg
level
laboratori
normal
rang
age
patient
necessarili
requir
igg
replac
therapi
satisfactori
specif
antibodi
concentr
vaccin
respons
mani
patient
antibodydefici
diseas
receiv
igiv
immunomodulatori
andor
antiinflammatori
properti
common
condit
igiv
use
pediatr
kawasaki
syndrom
igiv
also
use
toxigen
bacteri
infect
idiopath
thrombocytopen
purpura
itp
guillainbarr
syndrom
chronic
idiopath
demyelin
polyneuropathi
multifoc
motor
neuropathi
autoimmun
diseas
recent
evalu
evid
use
igiv
differ
condit
avail
elsewher
beyond
scope
articl
patient
confirm
antibodi
defici
may
maintain
without
igg
replac
period
time
use
rel
isol
prophylact
antibiot
expos
potenti
expos
viral
pathogen
eg
local
outbreak
chickenpox
mump
travel
develop
nation
patient
may
given
hyperimmun
eg
varicellazost
immun
globulin
standard
intramuscular
isg
prepar
approach
may
satisfactori
patient
reason
expect
overcom
development
delay
antibodi
product
recov
effect
treatment
regimen
complet
approach
consid
longterm
strategi
patient
clearli
diagnos
pid
diseas
igiv
found
help
certain
hivinfect
infant
prenat
treatment
reduc
matern
transmiss
hiv
improv
antivir
chemotherapi
set
major
use
isg
previou
era
plasma
often
parent
rel
use
antibodi
replac
children
pid
diseas
approach
rare
use
unit
state
mainli
time
effort
requir
sure
donor
plasma
free
bloodborn
pathogen
mayb
clinic
unappar
desir
provid
broad
rang
protect
antibodi
administ
immun
serum
globulin
intraven
subcutan
although
individu
dose
isg
may
given
intramuscularli
pain
risk
associ
deep
intramuscular
inject
limit
amount
administ
way
routin
therapi
intramuscular
rout
rare
use
although
mainstay
treatment
pid
diseas
year
igg
replacementaugment
regimen
employ
intraven
subcutan
administr
gener
dose
rang
mgkg
per
month
see
next
section
intraven
infus
igg
gener
well
toler
introduct
isg
prepar
could
given
safe
intraven
rout
earli
major
advanc
care
patient
pid
diseas
obstacl
overcom
includ
stabil
igg
molecul
would
aggreg
solut
purif
remov
trace
proinflammatori
molecul
activ
kallikreinkinin
clot
cascad
note
earlier
major
breakthrough
recognit
import
includ
excipi
amino
acid
andor
sugar
final
prepar
advers
reaction
igiv
relat
rate
infus
patient
naiv
igg
replac
interrupt
therapi
andor
activ
chronic
infect
increas
risk
infusionrel
advers
effect
effect
may
relat
part
format
antigenantibodi
complex
igg
given
andor
rapid
releas
lipopolysaccharid
compon
pathogen
alreadi
present
recipi
risk
reaction
may
reduc
make
sure
patient
afebril
activ
infect
treat
antibiot
begin
igiv
therapi
give
schedul
infus
studi
shown
incid
reaction
increas
patient
alreadi
receiv
therapi
given
differ
brand
igiv
minim
raterel
advers
effect
infus
start
slowli
rate
mlkgminut
equal
mgkgminut
solut
mgkgminut
solut
vital
sign
check
frequent
igiv
infus
particularli
naiv
patient
patient
remain
comfort
stabl
rate
infus
may
increas
stepwis
manner
usual
interv
maximum
toler
patient
prepar
label
administr
maximum
rate
mlkgminut
mgkg
minut
solut
respect
infusionrel
advers
reaction
frequent
mimic
sign
infect
includ
chill
even
rigor
arthralgia
andor
myalgia
headach
symptom
relat
rate
infus
slow
temporarili
stop
infus
may
allow
symptom
subsid
infus
resum
previous
toler
rate
precaut
fail
prevent
symptom
premed
antipyret
antihistamin
andor
corticosteroid
may
help
amelior
symptom
prolong
infus
medic
may
repeat
necessari
case
patient
report
system
reaction
includ
back
pain
chest
tight
feel
anxieti
sens
impend
doom
frequent
associ
flush
tachycardia
type
reaction
may
resembl
anaphylaxi
usual
involv
ige
therefor
type
reaction
term
anaphylactoid
key
differ
anaphylactoid
reaction
accompani
igiv
infus
true
igemedi
anaphylaxi
former
usual
associ
hypertens
rather
hypotens
would
expect
true
anaphylaxi
true
anaphylaxi
may
occur
patient
receiv
igiv
particularli
defici
iga
still
capac
produc
ige
true
anaphylaxi
occur
rare
may
life
threaten
therefor
practition
facil
administ
igiv
equip
treat
anaphylaxi
occur
risk
true
anaphylaxi
minim
screen
patient
complet
iga
defici
start
initi
infus
extrem
slowli
use
product
lowest
concentr
iga
test
patient
igeantibodi
iga
concern
mani
igadefici
patient
also
defici
immunoglobulin
isotyp
andor
specif
igg
antibodi
import
pathogen
patient
deni
isg
therapi
iga
defici
caution
use
administr
headach
may
occur
intraven
infus
sometim
repeatedli
follow
infus
much
hour
headach
may
charact
migrain
common
patient
suffer
migrain
independ
igiv
infus
rare
case
headach
follow
igiv
infus
may
accompani
meningismu
asept
mening
well
document
headach
sometim
may
prevent
use
corticosteroid
premed
day
two
follow
infus
use
triptan
migrain
treatment
addit
rare
complic
igiv
therapi
includ
transfusionrel
acut
lung
injuri
renal
failur
thrombos
comprehens
review
advers
effect
complic
igiv
infus
avail
read
everyon
administ
form
therapi
quit
often
patient
experi
headach
advers
effect
one
brand
igiv
may
toler
anoth
problem
therefor
switch
product
may
indic
obviat
advers
effect
convers
product
toler
equal
given
patient
substitut
made
care
supervis
gener
switch
product
slow
infus
rate
use
least
initi
pharmacokinet
igiv
well
describ
end
intraven
bolu
igg
igg
mostli
intravascular
concentr
expect
rise
mgdl
everi
mgkg
given
thu
common
peak
serum
igg
concentr
rise
much
mgdl
follow
dose
convent
replac
rang
mgkg
next
hour
igg
becom
distribut
total
extracellular
fluid
volum
serum
concentr
may
drop
reequilibr
igg
catabol
firstord
kinet
halflif
around
day
current
market
isg
contain
intact
igg
molecul
undergon
chemic
modif
thu
distribut
halflif
intraven
administ
igg
essenti
ident
endogen
produc
nativ
igg
reason
intraven
regimen
repeat
dose
interv
depend
dose
whether
endogen
igg
product
dose
interv
day
longer
frequent
leav
patient
serum
igg
concentr
rang
mgdl
even
less
end
dose
interv
mani
patient
report
flulik
symptom
increas
fatigu
andor
malais
trough
serum
igg
level
fall
low
may
increas
suscept
infect
time
situat
dose
may
increas
interv
shorten
higher
dose
andor
shorter
interv
also
necessari
patient
gastrointestin
renal
protein
loss
andor
increas
catabol
igg
discuss
later
although
mani
patient
toler
longterm
intraven
igg
replac
regimen
problem
survey
show
high
proport
patient
describ
condit
receiv
infus
inconveni
must
travel
hospit
infus
center
miss
school
work
andor
experi
difficulti
intraven
access
subcutan
regimen
offer
freedom
concern
bruton
treat
first
agammaglobulinem
patient
report
subcutan
inject
isg
investig
use
intramuscular
inject
becam
standard
care
nearli
decad
earli
use
small
batterypow
syring
driver
pump
give
subcutan
infus
isg
intend
intramuscular
use
sever
hour
describ
method
administr
free
pain
associ
deep
intramuscular
inject
much
better
toler
patient
higher
dose
could
administ
routin
gener
needl
extend
mm
skin
insert
perpendicularli
wide
varieti
special
needl
infus
set
avail
specif
igsc
therapi
depend
size
patient
ml
deliv
per
site
usual
hour
sever
site
may
use
infus
isg
weekli
dose
common
regimen
frequent
use
site
includ
abdomen
inner
anterior
thigh
back
arm
gener
site
one
pinch
inch
accept
subcutan
infus
ml
isg
nice
illustr
potenti
subcutan
infus
site
good
techniqu
insert
subcutan
needl
avail
onlin
nurs
staff
nation
institut
health
clinic
center
author
colleagu
found
size
patient
time
infus
given
import
factor
determin
maximum
volum
infus
given
site
thu
patient
may
give
ml
isg
singl
site
period
time
long
hour
patient
prefer
type
regimen
take
igsc
sleep
contrast
patient
may
prefer
take
small
dose
igsc
daili
basi
eg
push
ml
singl
site
sever
minut
seri
patient
use
isg
prepar
report
uhrainbow
babi
children
hospit
regimen
within
paramet
mlkgsitehour
basic
monthli
dose
igsc
calcul
wide
varieti
schedul
may
use
tailor
infus
regimen
patient
prefer
although
physician
patient
unit
state
adopt
intraven
rout
prepar
could
administ
intraven
becam
avail
patient
countri
experi
sever
advers
effect
intraven
prepar
continu
use
subcutan
rout
seriou
system
advers
effect
rare
problem
subcutan
infus
studi
report
less
infus
associ
system
advers
event
expertis
experi
necessari
establish
maintain
intraven
access
requir
subcutan
administr
low
risk
seriou
reaction
subcutan
infus
usual
administ
home
patient
parent
partner
major
disadvantag
subcutan
infus
limit
volum
isg
given
one
time
infus
given
home
andor
patient
perform
activ
patient
readili
adapt
weekli
frequent
infus
divis
monthli
dose
isg
weekli
even
frequent
infus
slower
absorpt
igg
circul
subcutan
site
intraven
bolus
tend
flatten
curv
serum
igg
concentr
time
seen
fig
elimin
high
peak
low
trough
associ
intermitt
intraven
bolus
amelior
infusionrel
advers
effect
also
feel
malais
fatigu
associ
low
trough
subcutan
infus
frequent
associ
local
swell
red
itch
burn
sensat
effect
rare
seriou
usual
subsid
sever
hour
patient
continu
subcutan
infus
local
reaction
tend
lessen
time
reason
chang
known
although
mani
patient
use
subcutan
rout
year
chronic
chang
fibrosi
lipodystrophi
infus
site
problemat
rare
abl
identifi
site
subcutan
igg
infus
given
hour
infus
complet
easier
patient
adjust
infus
schedul
school
work
schedul
rather
vice
versa
patient
longer
travel
infus
center
hospit
treatment
mani
patient
find
home
igsc
regimen
increas
sens
independ
autonomi
turn
respons
result
improv
qualiti
life
experienc
mani
patient
present
one
isg
prepar
market
unit
state
licens
subcutan
administr
small
seri
anecdot
report
howev
suggest
prepar
licens
administr
rout
well
toler
administ
subcutan
rout
sever
prepar
market
subcutan
use
europ
like
addit
product
concentr
high
even
avail
unit
state
next
year
comparison
volum
requir
give
compar
amount
igg
subcutan
intraven
rout
use
current
avail
prepar
given
box
along
sampl
subcutan
regimen
receiv
mgkg
per
month
g
igg
ml
intraven
solut
ml
intraven
solut
ml
subcutan
solut
subcutan
treatment
regimen
use
unit
dose
approach
deliv
approxim
g
igg
per
month
child
volum
solut
requir
approxim
ml
mlweek
one
two
bottl
solut
administ
one
infus
two
three
site
gweek
gmonth
ml
one
bottl
solut
administ
everi
fifth
day
six
timesmonth
one
two
site
gmonth
ml
two
bottl
solut
administ
everi
third
day
one
infus
one
site
gdose
gmonth
subcutan
regimen
receiv
approxim
gmonth
volum
solut
requir
approxim
ml
mlweek
one
bottl
administ
everi
third
day
one
two
site
gmonth
ml
administ
week
two
three
site
one
extra
infus
per
month
gmonth
ml
administ
daili
one
site
minut
push
gmonth
subcutan
regimen
receiv
approxim
gmonth
volum
solut
requir
ml
mlweek
administ
one
two
site
week
gweek
gmonth
ml
administ
everi
fifth
day
six
time
per
month
one
site
gmonth
ml
administ
everi
saturday
sunday
one
two
site
gmonth
ml
deliv
everi
monday
wednesday
friday
weekend
push
one
site
gmonth
efficaci
igg
replac
patient
pid
diseas
clearli
demonstr
studi
go
back
recent
survey
document
decreas
incid
pneumonia
patient
pid
diseas
put
igiv
treatment
dose
igg
given
standard
replac
regimen
increas
time
conveni
rout
administr
becom
practic
classic
studi
earli
british
medic
research
council
work
group
hypogammaglobulinemia
report
mgkgweek
effect
mgkgweek
prevent
febril
episod
otiti
media
pneumonia
differ
seem
suffici
clinic
import
warrant
widespread
use
higher
dosag
licens
studi
first
gener
intraven
product
unit
state
use
dose
rang
mgkgmonth
studi
roifman
colleagu
begin
show
patient
receiv
dose
mgkgmonth
achiev
trough
serum
igg
level
higher
mgdl
contrast
patient
cross
arm
receiv
mgkgmonth
sustain
trough
level
mgkg
turn
incid
major
minor
infect
reduc
greatli
patient
receiv
higher
dose
maintain
higher
level
similar
find
present
roifman
colleagu
recent
studi
patient
maintain
dose
igiv
select
physician
patient
receiv
higher
dose
maintain
higher
serum
trough
igg
level
fewer
infect
crossov
studi
compar
higher
igiv
dose
mgkg
month
adult
mgkgmonth
children
standard
dose
mgkgmonth
adult
mgkgmonth
children
show
statist
signific
reduct
incid
infect
cumul
day
ill
higherdos
group
licens
studi
current
gener
igiv
product
market
unit
state
use
dose
rang
mgkgmonth
reflect
dose
patient
receiv
enter
studi
regimen
result
annual
incid
seriou
bacteri
infect
meet
fda
definit
infectionpatientyear
less
overal
incid
infect
two
four
infect
per
patient
per
year
practic
paramet
promulg
jcaai
call
maintain
trough
serum
igg
level
mgdl
use
guidelin
level
typic
requir
dose
rang
mgkgmonth
patient
gastrointestin
andor
renal
protein
loss
higher
dose
andor
shorter
dose
interv
may
necessari
maintain
trough
level
mgdl
keep
patient
free
infect
higher
dosesdup
mgkgmonth
even
higherdar
recommend
patient
chronic
lung
andor
sinu
diseas
sever
report
progress
lung
diseas
dysfunct
patient
seem
clinic
free
pneumonia
report
symptom
chronic
bronchiti
bronchiectasi
report
consist
anecdot
experi
immunologist
larg
number
antibodydefici
patient
practic
close
monitor
may
includ
annual
highresolut
ct
scan
chest
formal
pulmonari
function
test
even
bronchoscopi
case
recommend
patient
diseas
current
era
expert
agre
prevent
pneumonia
seriou
infect
longer
suffici
indic
patient
manag
optim
effort
aim
normal
pulmonari
function
test
maxim
patient
abil
particip
full
rang
activ
prevent
progress
loss
lung
function
seem
warrant
prevent
andor
arrest
chronic
lung
sinu
diseas
patient
pid
diseas
frequent
requir
igg
replac
dose
higher
mgkgmonth
particularli
patient
alreadi
chronic
infect
structur
damag
therapi
start
patient
usual
benefit
comprehens
approach
includ
intens
antibiot
therapi
bronchodil
andor
inhal
corticosteroid
mucolyt
physic
therapi
improv
pulmonari
toilet
andor
sinu
surgeri
patient
select
lacunar
antibodi
defici
sever
hypogammaglobulinemia
per
se
still
requir
full
dose
isg
replac
maintain
adequ
titer
specif
antibodi
produc
similarli
antibodydefici
patient
high
igg
level
caus
polyclon
bcell
activ
occur
system
lupu
erythematosu
hiv
infect
patient
monoclon
gammopathi
actual
may
elev
serum
igg
level
still
need
full
dose
isg
replac
provid
spectrum
antibodi
necessari
protect
pathogen
may
expos
evid
suggest
bioavail
igg
decreas
given
subcutan
instead
intraven
tendenc
toward
higher
trough
level
weekli
subcutan
treatment
may
counterbal
decreas
efficaci
caus
tissu
degrad
igg
administ
subcutan
rout
howev
data
would
allow
determin
effect
maintain
higher
trough
level
fraction
cumul
dose
otherwis
would
given
singl
monthli
intraven
bolu
spars
particular
rel
import
high
peak
achiev
intermitt
bolus
unclear
two
major
efficaci
studi
singl
isg
product
current
licens
subcutan
administr
unit
state
perform
unit
state
pivot
trial
dose
increas
previou
intraven
dose
use
meet
fda
requir
area
curv
serum
igg
concentr
versu
time
rout
therapi
contrast
studi
perform
contemporan
europ
brazil
use
one
fourth
previou
monthli
intraven
dose
weekli
subcutan
dose
studi
equal
rate
infect
obtain
seriou
bacteri
infect
per
patient
per
year
infect
per
patient
per
year
overal
rang
subcutan
dose
span
mgkgweek
unit
state
studi
mgkgweek
europeanbrazil
studi
dose
rang
result
quit
consist
use
licens
trial
intraven
product
unit
state
past
year
patient
pid
diseas
requir
igg
replac
therapi
life
therefor
extrem
import
monitor
close
sure
treatment
associ
advers
event
littl
interfer
normal
activ
possibl
treatment
regimen
adequ
maintain
control
acut
infect
well
chronic
complic
underli
diseas
patient
acquir
bloodborn
infect
longterm
complic
therapi
begin
infus
particularli
intraven
infus
patient
reassess
import
note
chang
medic
signssymptom
chronic
acut
infect
advers
effect
occur
hour
previou
infus
note
chang
risk
factor
advers
effect
also
note
exampl
start
oral
contracept
increas
cigarett
smoke
may
increas
risk
thrombot
complic
igiv
infus
mani
patient
pid
diseas
chronic
bronchitisbronchiectasi
degre
revers
airway
obstruct
increas
secret
andor
bronchospasm
present
bronchodil
may
help
infus
author
colleagu
find
use
measur
record
expiratori
flow
rate
offic
spiromet
even
simpl
peak
flow
meter
help
assess
document
patient
statu
time
airway
open
possibl
begin
infus
may
help
prevent
seriou
problem
patient
experi
bronchospasmchest
tight
infus
patient
recent
febril
usual
help
pretreat
antipyret
signssymptom
acut
bacteri
infect
may
desir
defer
infus
day
initi
antibiot
therapi
avoid
shake
chill
sever
myalgiasheadach
infus
igg
may
need
help
resolv
infect
howev
delay
must
done
caution
patient
intercurr
acut
gastroenter
may
benefit
antispasmod
antiemet
treatment
infus
patient
may
requir
antipyret
antiemet
andor
antimigrain
premed
routin
basi
also
may
requir
corticosteroid
author
colleagu
often
latter
type
patient
take
dose
steroid
oral
sever
hour
infus
initi
patient
hydrat
statu
assess
care
usual
good
idea
record
patient
weight
time
infus
allow
comparison
possibl
dehydr
may
increas
risk
renal
complic
hyperviscos
thrombos
may
prudent
give
patient
intraven
fluid
actual
start
igiv
minim
risk
convers
patient
risk
congest
heart
failur
may
requir
defer
fluidsaltprotein
load
infus
recent
gain
weight
increas
dyspnea
andor
rale
chest
examin
andor
increas
peripher
edema
patient
congest
heart
failur
andor
fluid
retent
caus
may
benefit
administr
diuret
follow
infus
obvious
monitor
patient
close
infus
sign
dyspneafluid
retent
import
infus
begin
vital
sign
record
may
import
sure
patient
time
relax
adjust
ambient
condit
record
baselin
vital
sign
avoid
phenomenon
white
coat
hypertens
might
lead
misinterpret
decreas
blood
pressur
patient
relax
intraven
place
infus
run
patient
comfort
sleep
particularli
puls
decreas
rather
increas
blood
pressur
drop
even
expect
necessarili
mean
shock
immin
especi
patient
flush
dyspnea
intraven
infus
usual
start
mlkgminut
rate
increas
doubl
interv
maximum
mlkgminut
case
stepwis
increas
rate
made
patient
toler
infus
well
therefor
vital
sign
patient
condit
record
minut
rate
chang
maximum
rate
toler
patient
previou
infus
exceed
caution
import
realiz
stepwis
increas
rate
maximum
infus
rate
may
vari
patient
given
differ
product
therefor
patient
must
switch
product
close
monitor
patient
condit
vital
sign
necessari
infus
rate
andor
interv
rate
increas
may
requir
adjust
subcutan
infus
isg
rare
associ
system
advers
effect
signific
chang
vital
sign
inadvert
intravascular
administr
avoid
check
sure
blood
return
needl
actual
start
isg
infus
subcutan
regimen
total
monthli
dose
fraction
four
individu
dose
igg
given
slowli
adsorpt
subcutan
site
circul
slower
intraven
infus
rout
may
prefer
patient
risk
cardiovascular
thrombot
andor
renal
complic
mani
patient
complain
sever
headach
follow
intraven
isg
infus
less
sever
problem
subcutan
infus
migrain
still
may
occur
medic
may
requir
hour
infus
complet
vital
sign
usual
monitor
repeatedli
subcutan
infus
infus
site
observ
patient
time
infus
subcutan
infus
accompani
swell
without
red
mani
patient
report
local
pruritu
burn
sensat
symptom
may
obviat
treatment
antihistamin
infus
pretreat
corticosteroid
antiemet
rare
need
one
area
special
concern
subcutan
infus
risk
cellul
local
infect
infus
site
patient
swell
red
inject
fluid
may
lead
feel
fluctuanc
distinguish
manifest
infect
sometim
difficult
applic
warm
compress
gentl
massag
may
increas
local
circul
help
dissip
infus
product
gener
local
reaction
igsc
infus
subsid
within
hour
infus
complet
site
red
swell
warmth
increas
time
infus
consid
potenti
infect
observ
close
examin
profession
patient
selfinfus
home
alway
abl
contact
physician
nurs
oncal
case
may
help
ask
patient
mark
size
local
reaction
pen
potenti
enlarg
track
object
although
homecar
servic
physician
unit
state
prescrib
preload
epinephrin
injector
kept
home
practic
longer
follow
unit
kingdom
select
appropri
dose
discuss
previou
section
select
initi
dose
monitor
adequaci
time
individu
certainli
freedom
acut
bacteri
infect
would
readili
agreedupon
goal
mani
patient
chronic
bronchiti
bronchiectasi
seem
reactiv
airway
actual
may
experienc
progress
subclin
lung
diseas
similarli
patient
may
progress
eros
sinu
diseas
may
learn
live
symptom
monthli
measur
white
blood
cell
count
sediment
rate
creactiv
protein
often
use
assess
presenc
subclin
infect
turn
data
use
adjust
isg
antibiot
therapi
frequent
sputum
cultur
physic
examin
also
may
use
although
practic
paramet
jcaai
suggest
mgdl
suitabl
target
serum
igg
level
patient
treat
accord
clinic
condit
achiev
design
level
nevertheless
monitor
serum
igg
level
routin
interv
import
sever
reason
may
serv
marker
adequaci
therapi
enabl
comparison
one
regimen
anoth
thu
patient
experi
exacerb
underli
infect
andor
chronic
nonspecif
symptom
igg
trough
level
fall
certain
valu
treatment
intermitt
igiv
infus
valu
may
serv
target
subcutan
therapi
monitor
serum
igg
level
also
help
assess
whether
patient
increas
gastrointestin
renal
protein
loss
requir
higher
dose
shorter
dose
interv
maintain
protect
infect
patient
sever
hypogammaglobulinemia
per
se
andor
actual
elev
serum
igg
level
monoclon
gammopathi
nonspecif
polyclon
bcell
activ
monitor
trough
level
specif
antibodi
titer
eg
pneumococc
polysaccharid
may
prefer
use
total
igg
level
monitor
adequaci
therapi
besid
control
infect
import
rememb
patient
common
variabl
immunodefici
pid
diseas
greater
risk
develop
malign
autoimmun
thu
part
routin
monitor
patient
even
free
infect
includ
care
review
interv
histori
physic
examin
addit
select
patient
may
requir
radiograph
andor
radionuclid
studi
regular
interv
mani
case
immunologist
see
patient
much
frequent
physician
sometim
immunologist
default
becom
princip
caregiv
patient
must
dilig
sure
routin
health
screeningmainten
neglect
patient
primari
care
provid
one
clear
commun
requir
make
sure
development
lead
screen
perform
young
children
monitor
serum
lipid
risk
factor
cardiovascular
diseas
common
malign
ie
mammogram
stool
guaiac
test
prostat
examin
among
other
bone
densiti
perform
appropri
adult
patient
bone
densiti
monitor
may
particularli
import
postmenopaus
women
even
men
chronic
requir
oral
highdos
inhal
corticosteroid
isg
product
prepar
larg
pool
plasma
alway
threat
emerg
diseas
laps
standard
safeti
procedur
patient
monitor
sign
develop
potenti
bloodborn
diseas
includ
spongiform
encephalopathi
although
report
chronic
slowli
progress
neurodegen
diseas
patient
receiv
igiv
therapi
pid
diseas
clear
whether
condit
might
repres
chronic
viral
infect
central
nervou
system
complic
pid
diseas
per
se
transient
coomb
posit
report
certain
igiv
prepar
clinic
signific
hemolyt
anemia
rare
complic
igiv
therapi
patient
pid
diseas
especi
common
variabl
immunodefici
hyperigm
syndrom
also
may
develop
hematolog
andor
hepat
abnorm
result
underli
diseas
treatment
medic
obvious
import
follow
renal
function
patient
receiv
repeat
therapeut
infus
fluid
protein
care
initi
character
patient
baselin
includ
document
hematolog
hepat
renal
function
development
screen
thu
essenti
patient
antibodi
product
test
exposur
epsteinbarr
viru
cytomegaloviru
well
hiv
viral
hepatidi
document
therapi
begun
presenc
passiv
acquir
antibodi
may
make
document
difficult
document
patient
baselin
virolog
statu
may
import
clinic
medicoleg
implic
futur
monitor
complic
therapi
complet
blood
cell
count
hepat
renal
function
test
urinalysi
repeat
everi
month
monitor
bloodborn
infecti
diseas
nucleic
acid
test
polymeras
chain
reaction
revers
transcript
polymeras
chain
reaction
avail
prefer
serolog
screen
test
patient
pid
diseas
gener
antibodi
defici
may
produc
antibodi
expect
exposur
pathogen
test
probabl
repeat
year
besid
standard
prepar
polyclon
isg
sever
special
hyperimmun
globulin
avail
list
describ
detail
elsewher
gener
hyperimmun
globulin
prepar
plasma
individu
expos
accident
eg
snake
venom
convalesc
specif
infect
eg
chickenpox
whose
plasma
found
test
contain
high
titer
certain
desir
antibodi
antigen
plasma
drawn
person
specif
immun
unusu
potenti
import
pathogen
vaccinia
healthi
normal
donor
repeatedli
immun
common
vaccin
tetanu
toxoid
pediatrician
familiar
varicella
zoster
immun
globulin
use
antirh
prevent
alloimmun
mother
guidelin
plasma
donat
product
produc
step
use
assur
free
bloodborn
pathogen
standard
polyclon
isg
product
discuss
previous
although
great
progress
made
sinc
pain
intramuscular
inject
isg
mani
question
characterist
use
isg
remain
unansw
import
issu
mechan
action
polyclon
igg
inflammatori
autoimmun
diseas
remain
clear
extent
specif
modifi
monoclon
prepar
might
obviat
use
polyclon
igg
condit
report
describ
spectrum
antibodi
appropri
use
isg
prevent
andor
manag
influenza
scarc
even
less
clear
done
new
pandem
strain
emerg
popul
plasma
donor
shift
recov
natur
infect
measl
mump
similar
virus
childhood
immun
never
wildtyp
diseas
antibodi
level
isg
prepar
chang
concern
rais
well
protect
antibodydefici
individu
maintain
hand
steadili
increas
number
new
vaccin
introduc
recent
year
includ
meningococc
conjug
vaccin
human
papilloma
viru
vaccin
studi
antibodi
content
efficaci
standard
isg
prepar
prevent
infect
avail
addit
experi
rapid
worldwid
transmiss
sever
acut
respiratori
syndrom
west
nile
viru
infect
recent
year
threat
emerg
diseas
longer
exot
scienc
fiction
scenario
thu
product
isg
bloodderiv
product
optim
care
patient
pid
diseas
continu
evolv
advanc
largescal
product
polyclon
isg
prepar
last
decad
greatli
improv
manag
patient
pid
diseas
continu
develop
product
improv
safeti
toler
profil
allow
treatment
focu
qualiti
life
longterm
freedom
complic
pid
diseas
rather
freedom
sever
acut
infect
surviv
current
avail
isg
prepar
allow
routin
therapi
varieti
rout
regimen
tailor
suit
individu
patient
continu
vigil
requir
howev
problem
emerg
diseas
cost
avail
isg
like
present
continu
challeng
